MARINUS PHARMACEUTICALS, INC. - COMMON STOCK (MRNS)

CUSIP: 56854Q200

Q2 2025 13F Holders as of 30 Jun 2025

Holder snapshot 5 signals
Share change
+6,001
SEC-reported price per share
$0.54
Number of holders
1
Value change
+$3,239
Number of buys
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
54,731,500

Security key

56854Q200

Report period

Q2 2025

Institutions

1

Top holders

0

Ownership snapshot

Top reported holders of MRNS - MARINUS PHARMACEUTICALS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
SUVRETTA CAPITAL MANAGEME...
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
3/9
Latest evidence
07 Feb 2025
13D/G 3/4/5 Lead comparable stake: 5.5% 6 rows are not safely comparable across share classes. 13D/G row: SUVRETTA CAPITAL MANAGEMENT, LLC Showing 1-6 of 9 holder rows.

Quick read

SUVRETTA CAPITAL MANAGEMENT, LLC leads the comparable SEC ownership view at 5.5%.

3 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SUVRETTA CAPITAL MANAGEMENT, LLC's linked filing trail.
Comparable ownership Top 3
SUVRETTA CAPITAL MANAGEMENT, LLC 5.5%
VANGUARD GROUP INC 4.7%
TANG CAPITAL PARTNERS LP 3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 9 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
SUVRETTA CAPITAL MANAGEMENT, LLC
13D/G
5.5%
$1,662,437
3,022,612 shares
+$504,541 07 Feb 2025
VANGUARD GROUP INC
13D/G
The Vanguard Group
4.7%
$1,428,222
2,596,768 shares
$0 31 Dec 2024
TANG CAPITAL PARTNERS LP
13D/G
TANG CAPITAL MANAGEMENT, LLC
3%
$903,070
1,641,945 shares
$0 31 Dec 2024
Sarah B. Noonberg
3/4/5
Director
mixed-class rows
$60,348
24,550 shares
mixed-class rows
18 Jun 2024
Nicole Vitullo
3/4/5
Director
mixed-class rows
$57,527
18,817 shares
mixed-class rows
04 Feb 2022
Sara Nochur
3/4/5
Director
mixed-class rows
$56,710
23,700 shares
mixed-class rows
18 Jun 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Archived quarter

Historical 13F summary for Q2 2025

This older quarter remains available as an indexed ownership summary. Detailed holder rows are no longer kept in the hot table for this period.

There are no holders of MRNS - MARINUS PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .